Figure 2From: Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programmeKaplan–Meier analysis of progression-free survival among 74 patients receiving ipilimumab 10 mg/kg at Italian centres participating in an EAP. EAP expanded access programme, PFS progression-free survival.Back to article page